A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Mitsuhiko Iwamoto,Kosei Kimura,Satoru Tanaka,Daigo Yamamoto,Katsuhide Yoshidome,Hiroyuki Ogura,Risa Terasawa,Nobuki Matsunami,Yuko Takahashi,Toshikatsu Nitta,Takashi Morimoto,Hiroya Fujioka,Kanako Kawaguchi,Kazuhisa Uchiyama

Journal of Clinical Oncology（2018）

引用 0|浏览6

暂无评分

摘要

e13059Background: Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor ...

查看译文

关键词

metastatic breast cancer,second line chemotherapy,eribulin,breast cancer,single-arm,patient-reported

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要